Literature DB >> 7705106

Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity.

B Ceyhan1, T Celikel.   

Abstract

Although heparin is used as an anticoagulant, its biologic function has remained unclear since the 1920s. Glycosaminoglycan heparin possesses multiple noncoagulant properties, including anti-inflammatory actions, and it is possible that heparin may inhibit airway hyperreactivity. Thus, the purpose of the present investigation was to study the effect of inhaled heparin on methacholine-induced bronchoconstriction. Thirteen subjects (7 women, 6 men) with mild asthma were included in the study. Bronchial provocation tests were performed in a single-blind, crossover, randomized order and repeated 45 min after placebo or aerosolized heparin inhalation (1,000 U/kg). The heparin inhibited bronchoconstriction induced by methacholine. In the methacholine challenge test, heparin treatment resulted in an increase in the mean PD20 over placebo: 5.26 +/- 4.80 mg/mL vs 10.57 +/- 5.72 mg/mL (p < 0.0002). These data suggest that inhaled heparin may have an inhibitory role on methacholine bronchial challenge, possibly via a direct effect on smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705106     DOI: 10.1378/chest.107.4.1009

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Fungi in Mucoobstructive Airway Diseases.

Authors:  Evan Li; Cameron T Landers; Hui-Ying Tung; J Morgan Knight; Zachary Marshall; Amber U Luong; Antony Rodriguez; Farrah Kheradmand; David B Corry
Journal:  Ann Am Thorac Soc       Date:  2018-11

2.  Heparin normalizes allergen-induced nitric oxide deficiency and airway hyperresponsiveness.

Authors:  Harm Maarsingh; Jacob de Boer; Henk F Kauffman; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

3.  Low-molecular-weight heparin and unfractionated heparin decrease Th-1, 2, and 17 expressions.

Authors:  Jing-Ning Huang; Ming-Chin Tsai; Shun-Lung Fang; Margaret Dah-Tsyr Chang; Yu-Rou Wu; Jaw-Ji Tsai; Lin-Shien Fu; Heng-Kuei Lin; Yi-Jun Chen; Tsai-Wei Li
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

4.  Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics.

Authors:  Madhur D Shastri; Niall Stewart; Mathew Eapen; Gregory M Peterson; Syed Tabish R Zaidi; Nuri Gueven; Sukhwinder Singh Sohal; Rahul P Patel
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

5.  Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial.

Authors:  Somayyeh Nasiripour; Kheirollah Gholami; Sarah Mousavi; Abbas Mohagheghi; Mania Radfar; Mohammad Abdollahi; Zahra Khazaeipour; Mojtaba Mojtahedzadeh
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

Review 6.  Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports.

Authors:  Rahul P Patel; Madhur D Shastri; Long Chiau Ming; Syed Tabish R Zaidi; Gregory M Peterson
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.